

# Nick Holford Mbchb, Fracp

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4325857/publications.pdf>

Version: 2024-02-01

167  
papers

12,979  
citations

19636

61  
h-index

25770

108  
g-index

171  
all docs

171  
docs citations

171  
times ranked

8143  
citing authors

#	ARTICLE	IF	CITATIONS
1	Understanding the Dose-Effect Relationship. <i>Clinical Pharmacokinetics</i> , 1981, 6, 429-453.	1.6	994
2	Mechanism-Based Concepts of Size and Maturity in Pharmacokinetics. <i>Annual Review of Pharmacology and Toxicology</i> , 2008, 48, 303-332.	4.2	910
3	Kinetics of pharmacologic response. , 1982, 16, 143-166.		432
4	A Size Standard for Pharmacokinetics. <i>Clinical Pharmacokinetics</i> , 1996, 30, 329-332.	1.6	424
5	Mechanistic Basis of Using Body Size and Maturation to Predict Clearance in Humans. <i>Drug Metabolism and Pharmacokinetics</i> , 2009, 24, 25-36.	1.1	408
6	Human renal function maturation: a quantitative description using weight and postmenstrual age. <i>Pediatric Nephrology</i> , 2009, 24, 67-76.	0.9	406
7	A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. <i>Computer Methods and Programs in Biomedicine</i> , 1999, 59, 19-29.	2.6	318
8	The response to levodopa in parkinson's disease: Imposing pharmacological law and order. <i>Annals of Neurology</i> , 1996, 39, 561-573.	2.8	296
9	A Pharmacokinetic Standard for Babies and Adults. <i>Journal of Pharmaceutical Sciences</i> , 2013, 102, 2941-2952.	1.6	278
10	Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children. <i>British Journal of Anaesthesia</i> , 2004, 92, 208-217.	1.5	258
11	Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. <i>Blood</i> , 2006, 108, 3674-3681.	0.6	253
12	Clinical Pharmacokinetics and Pharmacodynamics of Warfarin. <i>Clinical Pharmacokinetics</i> , 1986, 11, 483-504.	1.6	249
13	Simulation of Clinical Trials. <i>Annual Review of Pharmacology and Toxicology</i> , 2000, 40, 209-234.	4.2	248
14	Clinical Pharmacokinetics of Ethanol. <i>Clinical Pharmacokinetics</i> , 1987, 13, 273-292.	1.6	223
15	Acetaminophen Developmental Pharmacokinetics in Premature Neonates and Infants. <i>Anesthesiology</i> , 2002, 96, 1336-1345.	1.3	220
16	Size, Myths and the Clinical Pharmacokinetics of Analgesia in Paediatric Patients. <i>Clinical Pharmacokinetics</i> , 1997, 33, 313-327.	1.6	180
17	Perioperative Pharmacodynamics of Acetaminophen Analgesia in Children. <i>Anesthesiology</i> , 1999, 90, 411-421.	1.3	170
18	Clinical Trial Simulation: A Review. <i>Clinical Pharmacology and Therapeutics</i> , 2010, 88, 166-182.	2.3	169

#	ARTICLE	IF	CITATIONS
19	A model for size and age changes in the pharmacokinetics of paracetamol in neonates, infants and children. <i>British Journal of Clinical Pharmacology</i> , 2000, 50, 125-134.	1.1	161
20	Population clinical pharmacology of children: modelling covariate effects. <i>European Journal of Pediatrics</i> , 2006, 165, 819-829.	1.3	158
21	Morphine pharmacokinetics and pharmacodynamics in preterm and term neonates: secondary results from the NEOPAIN trial. <i>British Journal of Anaesthesia</i> , 2008, 101, 680-689.	1.5	157
22	DRUGTREATMENTEFFECTS ONDISEASEPROGRESSION. <i>Annual Review of Pharmacology and Toxicology</i> , 2001, 41, 625-659.	4.2	151
23	Understanding dosing: children are small adults, neonates are immature children. <i>Archives of Disease in Childhood</i> , 2013, 98, 737-744.	1.0	148
24	Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance. <i>British Journal of Clinical Pharmacology</i> , 2007, 63, 75-84.	1.1	147
25	Influence of obesity on propofol pharmacokinetics: derivation of a pharmacokinetic model. <i>British Journal of Anaesthesia</i> , 2010, 105, 448-456.	1.5	146
26	Tips and traps analyzing pediatric PK data. <i>Paediatric Anaesthesia</i> , 2011, 21, 222-237.	0.6	141
27	Progression of motor and nonmotor features of Parkinson's disease and their response to treatment. <i>British Journal of Clinical Pharmacology</i> , 2012, 74, 267-283.	1.1	139
28	Acetaminophen analgesia in children: placebo effect and pain resolution after tonsillectomy. <i>European Journal of Clinical Pharmacology</i> , 2001, 57, 559-569.	0.8	131
29	The <i>SLCO1B1</i> rs4149032 Polymorphism Is Highly Prevalent in South Africans and Is Associated with Reduced Rifampin Concentrations: Dosing Implications. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 4122-4127.	1.4	130
30	Stereoselective Disposition and Glucuronidation of Propranolol in Humans. <i>Journal of Pharmaceutical Sciences</i> , 1982, 71, 699-704.	1.6	115
31	Busulfan in Infant to Adult Hematopoietic Cell Transplant Recipients: A Population Pharmacokinetic Model for Initial and Bayesian Dose Personalization. <i>Clinical Cancer Research</i> , 2014, 20, 754-763.	3.2	112
32	Negligible excretion of unchanged ketoprofen, naproxen, and probenecid in urine. <i>Journal of Pharmaceutical Sciences</i> , 1980, 69, 1254-1257.	1.6	105
33	Pharmacokinetics of rectal paracetamol after major surgery in children. <i>Paediatric Anaesthesia</i> , 1995, 5, 237-242.	0.6	102
34	Rectal paracetamol dosing regimens: determination by computer simulation. <i>Paediatric Anaesthesia</i> , 1997, 7, 451-455.	0.6	95
35	Volume Shifts and Protein Binding Estimates using Equilibrium Dialysis: Application to Prednisolone Binding in Humans. <i>Journal of Pharmaceutical Sciences</i> , 1983, 72, 1442-1446.	1.6	94
36	Quantitative justification for target concentration intervention - parameter variability and predictive performance using population pharmacokinetic models for aminoglycosides. <i>British Journal of Clinical Pharmacology</i> , 2004, 58, 8-19.	1.1	93

#	ARTICLE	IF	CITATIONS
37	External evaluation of population pharmacokinetic models of vancomycin in neonates: the transferability of published models to different clinical settings. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 1068-1080.	1.1	92
38	Importance of hematocrit for a tacrolimus target concentration strategy. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 65-77.	0.8	92
39	Population clinical pharmacology of children: general principles. <i>European Journal of Pediatrics</i> , 2006, 165, 741-746.	1.3	90
40	Results and validation of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1992, 89, 11471-11475.	3.3	89
41	Allometric size: The scientific theory and extension to normal fat mass. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 109, S59-S64.	1.9	88
42	Methodologic aspects of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1992, 89, 11466-11470.	3.3	87
43	Paracetamol plasma and cerebrospinal fluid pharmacokinetics in children. <i>British Journal of Clinical Pharmacology</i> , 1998, 46, 237-243.	1.1	87
44	Disease Progression and Pharmacodynamics in Parkinson Disease – Evidence for Functional Protection with Levodopa and Other Treatments. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2006, 33, 281-311.	0.8	86
45	Predicting concentrations in children presenting with acetaminophen overdose. <i>Journal of Pediatrics</i> , 1999, 135, 290-295.	0.9	80
46	Target concentration intervention: beyond Y2K. <i>British Journal of Clinical Pharmacology</i> , 1999, 48, 9-13.	1.1	79
47	Mechanisms of enhancement of the antitumour activity of melphalan by the tumour-blood-flow inhibitor 5,6-dimethylxanthenone-4-acetic acid. <i>Cancer Chemotherapy and Pharmacology</i> , 1997, 39, 541-546.	1.1	78
48	Safe and Effective Variability – A Criterion for Dose Individualization. <i>Therapeutic Drug Monitoring</i> , 2012, 34, 565-568.	1.0	75
49	Paracetamol and metabolite pharmacokinetics in infants. <i>European Journal of Clinical Pharmacology</i> , 2003, 59, 243-251.	0.8	74
50	Population pharmacokinetics and pharmacodynamics of linezolid-induced thrombocytopenia in hospitalized patients. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1758-1772.	1.1	74
51	A Time to Event Tutorial for Pharmacometricians. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2013, 2, 1-8.	1.3	73
52	Dexmedetomidine hemodynamics in children after cardiac surgery. <i>Paediatric Anaesthesia</i> , 2010, 20, 425-433.	0.6	70
53	Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors. <i>Clinical Pharmacology and Therapeutics</i> , 2002, 71, 334-348.	2.3	69
54	Limited predictability of amikacin clearance in extreme premature neonates at birth. <i>British Journal of Clinical Pharmacology</i> , 2006, 61, 39-48.	1.1	69

#	ARTICLE	IF	CITATIONS
55	Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease. <i>Movement Disorders</i> , 2002, 17, 961-968.	2.2	67
56	A Pharmacodynamic Model for the Time Course of Tumor Shrinkage by Gemcitabine + Carboplatin in Non-Small Cell Lung Cancer Patients. <i>Clinical Cancer Research</i> , 2008, 14, 4213-4218.	3.2	67
57	A comparison of bootstrap approaches for estimating uncertainty of parameters in linear mixed-effects models. <i>Pharmaceutical Statistics</i> , 2013, 12, 129-140.	0.7	67
58	Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 509-523.	1.1	67
59	Dosing in Children. <i>Clinical Pharmacology and Therapeutics</i> , 2010, 87, 367-370.	2.3	65
60	The Target Concentration Approach to Clinical Drug Development. <i>Clinical Pharmacokinetics</i> , 1995, 29, 287-291.	1.6	64
61	Investigating the pharmacodynamics of ketamine in children. <i>Paediatric Anaesthesia</i> , 2008, 18, 36-42.	0.6	64
62	Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent (quetiapine). <i>Pharmacology and Therapeutics</i> , 2000, 68, 568-577.	2.3	63
63	Prediction of morphine dose in humans. <i>Paediatric Anaesthesia</i> , 2012, 22, 209-222.	0.6	62
64	Quinidine pharmacokinetics in man: Choice of a disposition model and absolute bioavailability studies. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1979, 7, 315-330.	0.6	61
65	Levodopa Slows Progression of Parkinson's Disease. External Validation by Clinical Trial Simulation. <i>Pharmaceutical Research</i> , 2007, 24, 791-802.	1.7	59
66	Pharmacokinetics of prednisolone and endogenous hydrocortisone levels in cushingoid and non-cushingoid patients. <i>European Journal of Clinical Pharmacology</i> , 1981, 21, 235-242.	0.8	56
67	Modeling the norketamine metabolite in children and the implications for analgesia. <i>Paediatric Anaesthesia</i> , 2007, 17, 831-840.	0.6	55
68	Evaluation of bootstrap methods for estimating uncertainty of parameters in nonlinear mixed-effects models: a simulation study in population pharmacokinetics. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2014, 41, 15-33.	0.8	53
69	Caffeine Overdose in a Premature Infant: Clinical Course and Pharmacokinetics. <i>Anaesthesia and Intensive Care</i> , 1999, 27, 307-311.	0.2	51
70	ANALYSIS OF POPULATION PHARMACOKINETIC DATA USING NONMEM AND WinBUGS. <i>Journal of Biopharmaceutical Statistics</i> , 2004, 15, 53-73.	0.4	51
71	Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation. <i>British Journal of Clinical Pharmacology</i> , 2003, 55, 147-157.	1.1	50
72	The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 689-695.	0.8	50

#	ARTICLE	IF	CITATIONS
73	Dexmedetomidine pharmacokinetics in the obese. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 1501-1508.	0.8	48
74	Application of Clinical Trial Simulation to Compare Proof-of-Concept Study Designs for Drugs with a Slow Onset of Effect; An Example in Alzheimer's Disease. <i>Pharmaceutical Research</i> , 2006, 23, 2050-2059.	1.7	47
75	Dyskinesia and the antiparkinsonian response always temporally coincide. <i>Neurology</i> , 2010, 74, 1191-1197.	1.5	47
76	What is the best size predictor for dose in the obese child?. <i>Paediatric Anaesthesia</i> , 2017, 27, 1176-1184.	0.6	47
77	Tramadol and O-Desmethyl Tramadol Clearance Maturation and Disposition in Humans: A Pooled Pharmacokinetic Study. <i>Clinical Pharmacokinetics</i> , 2015, 54, 167-178.	1.6	45
78	Opiate receptor binding-effect relationship: Sufentanil and etorphine produce analgesia at the $\mu$ -site with low fractional receptor occupancy. <i>Brain Research</i> , 1984, 291, 317-324.	1.1	44
79	Dose-Dependent Elimination of Propranolol and its Major Metabolites in Humans. <i>Journal of Pharmaceutical Sciences</i> , 1983, 72, 725-732.	1.6	43
80	Optimizing Mycophenolic Acid Exposure in Kidney Transplant Recipients: Time for Target Concentration Intervention. <i>Transplantation</i> , 2019, 103, 2012-2030.	0.5	43
81	Postoperative analgesia using diclofenac and acetaminophen in children. <i>Paediatric Anaesthesia</i> , 2014, 24, 953-961.	0.6	42
82	Features and Toxicokinetics of Clozapine in Overdose. <i>Therapeutic Drug Monitoring</i> , 1998, 20, 92-97.	1.0	41
83	Washout and delayed start designs for identifying disease modifying effects in slowly progressive diseases using disease progression analysis. <i>Pharmaceutical Statistics</i> , 2009, 8, 225-238.	0.7	41
84	Disease progress and response to treatment as predictors of survival, disability, cognitive impairment and depression in Parkinson's disease. <i>British Journal of Clinical Pharmacology</i> , 2012, 74, 284-295.	1.1	41
85	TDM is dead. Long live TCI!. <i>British Journal of Clinical Pharmacology</i> , 2020, , .	1.1	40
86	Models for describing absorption rate and estimating extent of bioavailability: Application to cefetamet pivoxil. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1992, 20, 421-442.	0.6	39
87	Predicting weight using postmenstrual age $\hat{w}$ neonates to adults. <i>Paediatric Anaesthesia</i> , 2011, 21, 309-315.	0.6	39
88	Prednisone and prednisolone bioavailability in renal transplant patients. <i>Kidney International</i> , 1982, 21, 621-626.	2.6	38
89	Disease progression, drug action and Parkinson's disease: Why time cannot be ignored. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 207-216.	0.8	36
90	Theory-based pharmacokinetics and pharmacodynamics of S <sub>1</sub> and R <sub>2</sub> warfarin and effects on international normalized ratio: influence of body size, composition and genotype in cardiac surgery patients. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 823-835.	1.1	36

#	ARTICLE	IF	CITATIONS
91	Simulation of Correlated Continuous and Categorical Variables using a Single Multivariate Distribution. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2006, 33, 773-794.	0.8	35
92	Clinical pharmacology = disease progression + drug action. <i>British Journal of Clinical Pharmacology</i> , 2015, 79, 18-27.	1.1	33
93	Pharmacokinetic and Pharmacodynamic Changes During the First Four Years of Levodopa Treatment in Parkinson's Disease. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2005, 32, 459-484.	0.8	30
94	Nonlinear pharmacokinetics of piperacillin in healthy volunteers – implications for optimal dosage regimens. <i>British Journal of Clinical Pharmacology</i> , 2010, 70, 682-693.	1.1	30
95	The ghosts of departed quantities: approaches to dealing with observations below the limit of quantitation. <i>Statistics in Medicine</i> , 2012, 31, 4280-4295.	0.8	30
96	Pharmacokinetic-pharmacodynamic analysis of unbound disopyramide directly measured in serial plasma samples in man. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1984, 12, 559-573.	0.6	28
97	Pharmacokinetics of quinidine and three of its metabolites in man. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1984, 12, 1-21.	0.6	28
98	Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants. <i>Kidney International</i> , 1984, 25, 119-123.	2.6	27
99	Population Pharmacokinetics of Humanized Monoclonal Antibody HuCC49 <sup>+</sup> CH2 and Murine Antibody CC49 in Colorectal Cancer Patients. <i>Journal of Clinical Pharmacology</i> , 2007, 47, 227-237.	1.0	27
100	A combined pharmacokinetic model for the hypoxia-targeted prodrug PR-104A in humans, dogs, rats and mice predicts species differences in clearance and toxicity. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 1145-1155.	1.1	27
101	Modeling the Short- and Long-Duration Responses to Exogenous Levodopa and to Endogenous Levodopa Production in Parkinson's Disease. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2004, 31, 243-268.	0.8	26
102	The population pharmacokinetics of allopurinol and oxypurinol in patients with gout. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 1411-1421.	0.8	26
103	Pharmacokinetics of Paracetamol in Adults after Cardiac Surgery. <i>Anaesthesia and Intensive Care</i> , 1999, 27, 615-622.	0.2	25
104	Interpreting the results of Parkinson's disease clinical trials: Time for a change. <i>Movement Disorders</i> , 2011, 26, 569-577.	2.2	25
105	Importance of Within Subject Variation in Levodopa Pharmacokinetics: A 4Year Cohort Study in Parkinson's Disease. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2005, 32, 307-331.	0.8	24
106	Pharmacodynamic principles and the time course of immediate drug effects. <i>Translational and Clinical Pharmacology</i> , 2017, 25, 157.	0.3	24
107	Holford NHG and Sheiner LB – Understanding the Dose-Effect Relationship-Clinical Application of Pharmacokinetic-Pharmacodynamic Models, <i>Clin Pharmacokin</i> 6:429-453 (1981) – The Backstory. <i>AAPS Journal</i> , 2011, 13, 662-664.	2.2	23
108	Getting the dose right for obese children. <i>Archives of Disease in Childhood</i> , 2017, 102, 54-55.	1.0	23

#	ARTICLE	IF	CITATIONS
109	Lack of Association of Single-Nucleotide Polymorphisms in <i>Pregnane X Receptor</i> , <i>Hepatic Nuclear Factor 4<math>\alpha</math></i> , and <i>Constitutive Androstane Receptor</i> with Docetaxel Pharmacokinetics. <i>Clinical Cancer Research</i> , 2007, 13, 7126-7132.	3.2	21
110	Does saturable formation of gemcitabine triphosphate occur in patients?. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 63, 55-64.	1.1	21
111	Time for Quantitative Clinical Pharmacology: A Proposal for a Pharmacometrics Curriculum. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 82, 103-105.	2.3	20
112	Pharmacometrics: Opportunity for Reducing Disease Burden in the Developing World: The Case of Africa. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2013, 2, 1-4.	1.3	19
113	Moclobemide. <i>Journal of Clinical Psychopharmacology</i> , 1995, 15, 84S-94S.	0.7	19
114	Quinidine decreases both renal and metabolic clearance of digoxin. <i>American Journal of Cardiology</i> , 1980, 45, 453.	0.7	17
115	Aspects of Theophylline Clearance in Children. <i>Anaesthesia and Intensive Care</i> , 1997, 25, 497-501.	0.2	17
116	Investigations using logistic regression models on the effect of the LMA on morphine induced vomiting after tonsillectomy. <i>Paediatric Anaesthesia</i> , 2000, 10, 633-638.	0.6	17
117	The Pharmacokinetics of Theophylline in Premature Neonates During the First Few Days After Birth. <i>Therapeutic Drug Monitoring</i> , 1999, 21, 598.	1.0	16
118	A pharmacokinetic model to predict the PK interaction of L-dopa and benserazide in rats. <i>Pharmaceutical Research</i> , 2001, 18, 1174-1184.	1.7	15
119	Population pharmacokinetic and pharmacodynamic modelling of the effects of nicorandil in the treatment of acute heart failure. <i>British Journal of Clinical Pharmacology</i> , 2008, 66, 352-365.	1.1	15
120	Pharmacodynamic principles and target concentration intervention. <i>Translational and Clinical Pharmacology</i> , 2018, 26, 150.	0.3	15
121	Negligible impact of birth on renal function and drug metabolism. <i>Paediatric Anaesthesia</i> , 2018, 28, 1015-1021.	0.6	14
122	PKPD Model of Interleukin-21 Effects on Thermoregulation in Monkeys Application and Evaluation of Stochastic Differential Equations. <i>Pharmaceutical Research</i> , 2007, 24, 298-309.	1.7	13
123	Pharmacodynamic principles and the time course of delayed and cumulative drug effects. <i>Translational and Clinical Pharmacology</i> , 2018, 26, 56.	0.3	13
124	Review: Efficient Rehabilitation Trial Designs Using Disease Progress Modeling: A Pediatric Traumatic Brain Injury Example. <i>Neurorehabilitation and Neural Repair</i> , 2010, 24, 225-234.	1.4	12
125	Comment on Pharmacokinetic Studies in Neonates: The Utility of an Opportunistic Sampling Design. <i>Clinical Pharmacokinetics</i> , 2015, 54, 1287-1288.	1.6	11
126	Volume of Distribution. <i>Translational and Clinical Pharmacology</i> , 2016, 24, 74.	0.3	11



#	ARTICLE	IF	CITATIONS
127	Leaving no stone unturned, or extracting blood from stone?. Paediatric Anaesthesia, 2010, 20, 1-6.	0.6	10
128	A hemodynamic model to guide blood pressure control during deliberate hypotension with sodium nitroprusside in children. Frontiers in Pharmacology, 2015, 6, 151.	1.6	10
129	Clearance. Translational and Clinical Pharmacology, 2015, 23, 42.	0.3	9
130	Clinical Pharmacology: Principles and practice of drug therapy in medical education. British Journal of Clinical Pharmacology, 2002, 54, 1-2.	1.1	8
131	Relative Bioavailability of Chlorthalidone in Humans: Adverse Influence of Polyethylene Glycol. Journal of Pharmaceutical Sciences, 1982, 71, 533-535.	1.6	7
132	Disease progression and neuroscience. Journal of Pharmacokinetics and Pharmacodynamics, 2013, 40, 369-376.	0.8	7
133	Absorption and Half-Life. Translational and Clinical Pharmacology, 2016, 24, 157.	0.3	7
134	Treatment response and disease progression. Translational and Clinical Pharmacology, 2019, 27, 123.	0.3	7
135	Wide size dispersion and use of body composition and maturation improves the reliability of allometric exponent estimates. Journal of Pharmacokinetics and Pharmacodynamics, 2022, 49, 151-165.	0.8	7
136	Gastrointestinal absorption of quinidine from some solutions and commercial tablets. Journal of Pharmacokinetics and Pharmacodynamics, 1980, 8, 243-255.	0.6	6
137	Pharmacokinetics and pharmacodynamics of quinidine and its metabolite, quinidine-N-oxide, in beagle dogs. European Journal of Drug Metabolism and Pharmacokinetics, 1984, 9, 315-324.	0.6	6
138	Quantitative model for the blood pressure-lowering interaction of valsartan and amlodipine. British Journal of Clinical Pharmacology, 2016, 82, 1557-1567.	1.1	6
139	Determination of maximum effect. Clinical Pharmacology and Therapeutics, 2002, 71, 304-304.	2.3	6
140	The Absence of Effect of Azathioprine on Prednisolone Pharmacokinetics Following Maintenance Prednisone Doses in Kidney Transplant Patients. American Journal of Kidney Diseases, 1984, 3, 425-429.	2.1	5
141	Dose Response: Pharmacokinetic-Pharmacodynamic Approach. , 2006, , 73-88.		5
142	Pharmacokinetic variability due to environmental differences. Translational and Clinical Pharmacology, 2017, 25, 59.	0.3	5
143	The Effect of Size, Maturation, Global Asphyxia, Cerebral Ischemia, and Therapeutic Hypothermia on the Pharmacokinetics of High-Dose Recombinant Erythropoietin in Fetal Sheep. International Journal of Molecular Sciences, 2020, 21, 3042.	1.8	5
144	Rectal Acetaminophen Pharmacokinetics. Anesthesiology, 1998, 88, 1131-1131.	1.3	4

#	ARTICLE	IF	CITATIONS
145	Concentration controlled therapy. International Congress Series, 2001, 1220, 135-144.	0.2	4
146	Evaluation of a morphine maturation model for the prediction of morphine clearance in children. British Journal of Clinical Pharmacology, 2011, 72, 518-520.	1.1	4
147	Disease Progress Models. , 2007, , 313-321.		4
148	Input From the Deep South Compartment. Clinical Pharmacokinetics, 1995, 29, 139-141.	1.6	3
149	Relationship of Muscle Strength to Potassium Concentration in a Hypokalaemic Infant. Anaesthesia and Intensive Care, 1997, 25, 525-527.	0.2	3
150	Modeling Helps in Understanding Antidepressants. Clinical Pharmacology and Therapeutics, 2012, 92, 155-156.	2.3	3
151	Tacrolimus pharmacokinetics after kidney transplantation â€“ Influence of changes in haematocrit and steroid dose. British Journal of Clinical Pharmacology, 2015, 80, 1475-1476.	1.1	3
152	Response to Râ€warfarin anticoagulant effect. British Journal of Clinical Pharmacology, 2017, 83, 2305-2306.	1.1	3
153	Pharmacometrics in Australasiaâ€”Twenty Years of Population Approach Group of Australia and New Zealand. CPT: Pharmacometrics and Systems Pharmacology, 2019, 8, 701-704.	1.3	3
154	Non-stationary pharmacokinetics of bupivacaine during continuous interpleural infusion. Acute Pain, 1997, 1, 15-20.	0.1	2
155	The International Society of Pharmacometrics. Journal of Pharmacokinetics and Pharmacodynamics, 2013, 40, 3-4.	0.8	2
156	Time Course of Drug Response. , 2007, , 301-311.		1
157	Response to â€Validation and Assessment of Predictive Performance in Simulation Models of Clinical Trialsâ€, Clinical Pharmacology and Therapeutics, 2011, 89, 488-488.	2.3	1
158	Disease Progress Models. , 2012, , 369-379.		1
159	Authors' response to <sc>M</sc>arras and <sc>O</sc>akes, â€piecing together the puzzle of progression and mortality in <sc>P</sc>arkinson's diseaseâ€™. British Journal of Clinical Pharmacology, 2013, 75, 1370-1371.	1.1	1
160	V <sub>z</sub> , THE TERMINAL PHASE VOLUME: TIME FOR ITS TERMINAL PHASE?1*. Journal of Biopharmaceutical Statistics, 2002, 11, 373-375.	0.4	1
161	Disease progress models. , 2022, , 389-403.		1
162	Pharmacometrics: The Science of Quantitative Pharmacology by E. I. Ette and P. J. Williams. Biometrics, 2008, 64, 313-313.	0.8	0

#	ARTICLE	IF	CITATIONS
163	Time Course of Drug Response. , 2012, , 357-367.		0
164	Response to Diaz and de Leon "The Mathematics of Drug Dose Individualization Should be Built With Random Effects Linear Models" Therapeutic Drug Monitoring, 2013, 35, 873-874.	1.0	0
165	Time course of drug response. , 2022, , 377-387.		0
166	Commentary on Pharmacologically Meaningful Half-Life. Journal of Clinical Pharmacology, 2022, 62, 833-834.	1.0	0
167	Important lack of difference in tacrolimus and mycophenolic acid pharmacokinetics between Aboriginal and Caucasian kidney transplant recipients. Nephrology, 0, , .	0.7	0